Novartis aims for Q2 Bexsero filing; Boehringer wins NICE nod on first cancer drug; Merck nabs FDA approval for IV Noxafil;

@FiercePharma: Best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @FiercePharma

@TracyStaton: Tops at FiercePharma Wed.: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. More | Follow @TracyStaton

@EricPFierce: New twist on KV vs FDA over Makena. FDA cites compounder. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> After a Drexel University student died of a meningitis B infection, Novartis ($NVS) said it's aiming to file for FDA approval for its vaccine against the strain, Bexsero, during the second quarter. Report

> Germany-based Boehringer Ingelheim's first cancer drug, Giotrif (afatinib), won a draft recommendation from U.K. cost-effectiveness watchdogs as a treatment for non-small cell lung cancer. Report

> The FDA approved Merck's ($MRK) antifungal treatment Noxafil for intravenous use. Report

> Japan's Eisai plans to amp up production at a Vizag, India, plant to 2 billion tablets by 2016. Report

> Infectious disease prevalence in Latin America, plus a lack of available treatments, opens up opportunities for drugmakers in the region, a Frost & Sullivan study found. Report

> The European Federation of Pharmaceutical Industries and Associations (EFPIA) has mounted a social media campaign aimed at members of the European Parliament. Report

> Spain's Almirall plans to issue €325 million ($453 million) in senior notes. Report

Medical Device News

@FierceMedDev: Staar got key FDA panel backing for its new ocular lens. Chances for approval now pretty high. More | Follow @FierceMedDev

@MarkHFierce: Boston Scientific gained a CE mark for new MRI-safe pacer leads. News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: NeuroDerm preps for Parkinson's patch PhII trial. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Following the 5-second rule for food is like playing Russian roulette with your gut, says one molecular biologist. Article | Follow @EmilyWFierce

> Smith & Nephew clears a major U.S. regulatory hurdle for ArthroCare merger. Story

> Samsung's Galaxy S5 smartphone escapes med device label in S. Korea. More

Biotech News

@FierceBiotech: ICYMI over the weekend: Chimerix started the week as a punching bag, then pulls off a TKO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers inks a $350M deal to pair with FivePrime on immuno-oncology gold rush. Story | Follow @JohnCFierce

@DamianFierce: Amgen hits the mark in another of its 14 PhIII studies of the PCSK9-blocking evolocumab. Release | Follow @DamianFierce

@EmilyMFierce: NIH cuts, sequestration hampering cancer research. Story | Follow @EmilyMFierce

> Intercept scores a PhIII win for lead drug following Friday night frights. More

> Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in PhIII. Article

CRO News

> Charles River snaps up Galapagos' CRO biz for $179M. News

> Clinipace dives into Asia with Choice Pharma buyout. Story

> WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals. Article

> Post-merger BioClinica looks to corner the imaging market. Piece

> PPD lands a federal bioterror deal worth up to $100M. News

> Meet DPx, the result of a $2.6B CMO merger. Brief

Biotech IT News

> Illumina likely to start charging for BaseSpace storage and processing in 2014. Story

> IMS: Big Pharma must turn to tech to cut $36B from their operating costs. Article

> Public enthusiastic--but wary--about sharing personal health data. Survey

> The rise of the Silicon Valley biocomputing startup. Piece

> Drop in federal funding threatens 22 jobs at the Broad Institute. Story

> Genome data nonprofit aims to raise $25,000 through crowdfunding. Brief

And Finally... The incidence of colon cancer plunged 30% over the past decade in 50-and-older Americans as more people had colonoscopies. Report

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in non-diabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.